Stockscreener 앱 받기
2.3662
11.52%
0.1962
전일 마감가:
$2.17
열려 있는:
$2.32
하루 거래량:
125.64K
Relative Volume:
0.11
시가총액:
$428.34M
수익:
$109.16M
순이익/손실:
$-107.78M
주가수익비율:
-2.1389
EPS:
-1.1063
순현금흐름:
$-95.45M
1주 성능:
+2.36%
1개월 성능:
-2.25%
6개월 성능:
+301.85%
1년 성능:
+288.33%
1일 변동 폭
$2.29
$2.42
1주일 범위
$2.12
$2.34
52주 변동 폭
$0.435
$3.04
Century Therapeutics Inc Stock (IPSC) Company Profile
명칭
Century Therapeutics Inc
전화
215-981-4000
주소
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
2.375 | 407.60M | 109.16M | -107.78M | -95.45M | -1.1063 |
VRTX
Vertex Pharmaceuticals Inc
|
436.41 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
633.69 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.84 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.61 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.60 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | TD Cowen | Buy |
| 2024-08-08 | 개시 | Rodman & Renshaw | Buy |
| 2023-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-12-27 | 개시 | Chardan Capital Markets | Buy |
| 2022-10-31 | 개시 | Guggenheim | Buy |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-05-23 | 개시 | H.C. Wainwright | Buy |
| 2022-05-12 | 개시 | William Blair | Mkt Perform |
| 2021-07-13 | 개시 | BofA Securities | Buy |
| 2021-07-13 | 개시 | JP Morgan | Overweight |
| 2021-07-13 | 개시 | Piper Sandler | Overweight |
모두보기
Century Therapeutics Inc 주식(IPSC)의 최신 뉴스
This GE Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Mizuho initiates Century Therapeutics stock coverage at Outperform - Investing.com
Mizuho initiates Century Therapeutics stock coverage at Outperform By Investing.com - Investing.com Canada
Century Advances Diabetes Cell Therapy Toward Human Trials - MyChesCo
IPSC Stock Price, Quote & Chart | CENTURY THERAPEUTICS INC (NASDAQ:IPSC) - ChartMill
Century Therapeutics Q1 2026 Earnings: EPS Surpasses Estimates as Pipeline Progress ContinuesRising Community Picks - Newser
IPSC (NASDAQ: IPSC) resale supplement substitutes Point72 with SILV Fund - Stock Titan
Century Therapeutics (IPSC) CEO has 31,172 shares withheld to cover RSU tax obligations - Stock Titan
H.C. Wainwright Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock - MSN
Century Therapeutics (IPSC) Stock: Slides -1.68%, Support at $2.22 2026-05-15Professional Trade Ideas - newser.com
Point72 group reports 5.96M-share stake in Century Therapeutics (IPSC) - Stock Titan
RTW Investments and R. Wong report 7.1% stake in Century Therapeutics (IPSC) - Stock Titan
Century Therapeutics 1Q Research and Development Expenses $17.1M >IPSC - Moomoo
Versant Venture Management, LLC's Century Therapeutics Inc(IPSC) Holding History - GuruFocus
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors - Investing News Network
Piper Sandler Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Century Therapeutics (IPSC) Gains +1.80% — Support Holds at $2.20 2026-05-14Long Setup - newser.com
Century Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Forward-Looking Statements - Minichart
Century Therapeutics Reports First Quarter Financial Results and Business Updates - Investing News Network
Century Therapeutics Reports Q1 2026 Financial Results, Advances iPSC-Derived Diabetes and Cancer Therapies, Cash Runway to 2029 - Minichart
Century Therapeutics Q1 Earnings Beat Expectations - Intellectia AI
Century Therapeutics reports Q1 net loss $21.6M, cash runway into Q1 2029 - TradingView
Century Therapeutics 1Q 2026: Revenue ($22.26M), Net income ($21.65M), EPS ($0.11) — 10-Q Summary - TradingView
Century Therapeutics posts smaller-than-expected Q1 net loss on lower R&D spend - TradingView
Century Therapeutics (NASDAQ: IPSC) swings to Q1 2026 loss as prior collaboration revenue rolls off - Stock Titan
Century Therapeutics (IPSC) swings to Q1 2026 loss as one-time collaboration revenue ends - Stock Titan
Press Release: Century Therapeutics Reports First Quarter Financial Results and Business Updates - Moomoo
TradingKey - TradingKey
Douglas Carr, SVP at Century Therapeutics, sells $618 in stock By Investing.com - Investing.com South Africa
Douglas Carr, SVP at Century Therapeutics, sells $618 in stock - Investing.com India
SVP at Century Therapeutics (IPSC) sells shares to cover taxes - Stock Titan
How will Century Therapeutics (IPSC) earnings compare to expectations | Q4 2025: Better Than ExpectedROE - newser.com
Wall Street Zen Upgrades Century Therapeutics (NASDAQ:IPSC) to Hold - MarketBeat
H.C. Wainwright Increases Century Therapeutics Price Target to Five Dollars - HarianBasis.co
Century Therapeutics Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC) - Insider Monkey
Century Therapeutics Selected for Oral Presentation of CNTY?813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions - Investing News Network
Century Therapeutics to present diabetes therapy data at ADA - Investing.com
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions - The Manila Times
Century Therapeutics to present diabetes therapy data at ADA By Investing.com - Investing.com Canada
Century Therapeutics (NASDAQ: IPSC) sets 2026 virtual meeting and share authorization vote - Stock Titan
Century Therapeutics (NASDAQ:IPSC) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Century Therapeutics: A Biotech With Interesting Optionality Opportunities (NASDAQ:IPSC) - Seeking Alpha
iPSC-Derived NK Cells Pipeline Set to Transform Cancer Immunotherapy Landscape with 15+ Emerging Therapies and Strong Innovation Momentum from Century Therapeutics, Fate Therapeutics | DelveInsight - Barchart.com
What is HC Wainwright's Estimate for IPSC Q1 Earnings? - MarketBeat
IPSC Century Therapeutics Inc. posts narrower Q4 2025 loss than expected, shares gain 6.56 percent in daily trading.Margin of Safety - UBND thành phố Hải Phòng
Arrowhead Pharmaceuticals To Rally Over 44%? Here Are 10 Top Analyst Forecasts For Tuesday - Sahm
IPSC Maintained by HC Wainwright & Co. -- Price Target Raised to $5.00 - GuruFocus
Century Therapeutics, Inc. (NASDAQ:IPSC) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
H.C. Wainwright raises Century Therapeutics price target on diabetes therapy potential - Investing.com Canada
Century Therapeutics Inc (IPSC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
2.22%
자본화:
|
볼륨(24시간):